185 related articles for article (PubMed ID: 21439954)
1. Small tyrosine kinase inhibitors interrupt EGFR signaling by interacting with erbB3 and erbB4 in glioblastoma cell lines.
Carrasco-García E; Saceda M; Grasso S; Rocamora-Reverte L; Conde M; Gómez-Martínez A; García-Morales P; Ferragut JA; Martínez-Lacaci I
Exp Cell Res; 2011 Jun; 317(10):1476-89. PubMed ID: 21439954
[TBL] [Abstract][Full Text] [Related]
2. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling.
Chakravarti A; Loeffler JS; Dyson NJ
Cancer Res; 2002 Jan; 62(1):200-7. PubMed ID: 11782378
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3'-kinase and distinct from that induced by hypoxia.
Maity A; Pore N; Lee J; Solomon D; O'Rourke DM
Cancer Res; 2000 Oct; 60(20):5879-86. PubMed ID: 11059786
[TBL] [Abstract][Full Text] [Related]
4. Blockage of epidermal growth factor receptor by quinazoline tyrosine kinase inhibitors suppresses growth of human hepatocellular carcinoma.
Liu Y; Poon RT; Shao W; Sun X; Chen H; Kok TW; Fan ST
Cancer Lett; 2007 Apr; 248(1):32-40. PubMed ID: 16837130
[TBL] [Abstract][Full Text] [Related]
5. Growth stimulation of non-small cell lung cancer cell lines by antibody against epidermal growth factor receptor promoting formation of ErbB2/ErbB3 heterodimers.
Maegawa M; Takeuchi K; Funakoshi E; Kawasaki K; Nishio K; Shimizu N; Ito F
Mol Cancer Res; 2007 Apr; 5(4):393-401. PubMed ID: 17426253
[TBL] [Abstract][Full Text] [Related]
6. Adenosine diphosphate-ribosylation factor 6 is required for epidermal growth factor-induced glioblastoma cell proliferation.
Li M; Wang J; Ng SS; Chan CY; He ML; Yu F; Lai L; Shi C; Chen Y; Yew DT; Kung HF; Lin MC
Cancer; 2009 Nov; 115(21):4959-72. PubMed ID: 19642173
[TBL] [Abstract][Full Text] [Related]
7. Tyrphostin AG1478 suppresses proliferation and invasion of human breast cancer cells.
Zhang YG; Du Q; Fang WG; Jin ML; Tian XX
Int J Oncol; 2008 Sep; 33(3):595-602. PubMed ID: 18695891
[TBL] [Abstract][Full Text] [Related]
8. EGFR codon 497 polymorphism - implications for receptor sensitivity to inhibitors in HNSCC cell lines.
Krohn V; Wiegand S; Werner JA; Mandic R
Anticancer Res; 2011 Jan; 31(1):59-65. PubMed ID: 21273581
[TBL] [Abstract][Full Text] [Related]
9. Blockade of the epidermal growth factor receptor tyrosine kinase activity by quercetin and luteolin leads to growth inhibition and apoptosis of pancreatic tumor cells.
Lee LT; Huang YT; Hwang JJ; Lee PP; Ke FC; Nair MP; Kanadaswam C; Lee MT
Anticancer Res; 2002; 22(3):1615-27. PubMed ID: 12168845
[TBL] [Abstract][Full Text] [Related]
10. Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis.
Zhou Y; Li S; Hu YP; Wang J; Hauser J; Conway AN; Vinci MA; Humphrey L; Zborowska E; Willson JK; Brattain MG
Cancer Res; 2006 Jan; 66(1):404-11. PubMed ID: 16397255
[TBL] [Abstract][Full Text] [Related]
11. Effect of epidermal growth factor receptor inhibitor alone and in combination with cisplatin on growth of vulvar cancer cells.
Kim SH; Song YC; Kim SH; Jo H; Song YS
Ann N Y Acad Sci; 2009 Aug; 1171():642-8. PubMed ID: 19723115
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of F90, an epidermal growth factor receptor tyrosine kinase inhibitor, on glioblastoma cell line SHG-44.
Liu FJ; Gui SB; Li CZ; Sun ZL; Zhang YZ
Chin Med J (Engl); 2008 Sep; 121(17):1702-6. PubMed ID: 19024103
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-8 stimulates cell proliferation in non-small cell lung cancer through epidermal growth factor receptor transactivation.
Luppi F; Longo AM; de Boer WI; Rabe KF; Hiemstra PS
Lung Cancer; 2007 Apr; 56(1):25-33. PubMed ID: 17175059
[TBL] [Abstract][Full Text] [Related]
14. EGF receptor inhibitors increase ErbB3 mRNA and protein levels in breast cancer cells.
Grøvdal LM; Kim J; Holst MR; Knudsen SL; Grandal MV; van Deurs B
Cell Signal; 2012 Jan; 24(1):296-301. PubMed ID: 21951604
[TBL] [Abstract][Full Text] [Related]
15. Histone Deacetylase Inhibitors Resensitize EGFR/EGFRvIII-Overexpressing, Erlotinib-Resistant Glioblastoma Cells to Tyrosine Kinase Inhibition.
Liffers K; Kolbe K; Westphal M; Lamszus K; Schulte A
Target Oncol; 2016 Feb; 11(1):29-40. PubMed ID: 26032687
[TBL] [Abstract][Full Text] [Related]
16. Glioblastoma stem-like cell lines with either maintenance or loss of high-level EGFR amplification, generated via modulation of ligand concentration.
Schulte A; Günther HS; Martens T; Zapf S; Riethdorf S; Wülfing C; Stoupiec M; Westphal M; Lamszus K
Clin Cancer Res; 2012 Apr; 18(7):1901-13. PubMed ID: 22316604
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor family (EGFR, ErbB2-4) in gliomas and meningiomas.
Andersson U; Guo D; Malmer B; Bergenheim AT; Brännström T; Hedman H; Henriksson R
Acta Neuropathol; 2004 Aug; 108(2):135-42. PubMed ID: 15148612
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor pathway gene expressions and biological response of glioblastoma multiforme cell lines to erlotinib.
Halatsch ME; Löw S; Hielscher T; Schmidt U; Unterberg A; Vougioukas VI
Anticancer Res; 2008; 28(6A):3725-8. PubMed ID: 19189656
[TBL] [Abstract][Full Text] [Related]
19. EGFR inhibition using gefitinib is not active in neuroblastoma cell lines.
Rössler J; Odenthal E; Geoerger B; Gerstenmeyer A; Lagodny J; Niemeyer CM; Vassal G
Anticancer Res; 2009 Apr; 29(4):1327-33. PubMed ID: 19414383
[TBL] [Abstract][Full Text] [Related]
20. PTPIP51 levels in glioblastoma cells depend on inhibition of the EGF-receptor.
Petri MK; Brobeil A; Planz J; Bräuninger A; Gattenlöhner S; Nestler U; Stenzinger A; Paradowska A; Wimmer M
J Neurooncol; 2015 May; 123(1):15-25. PubMed ID: 25862004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]